Consensus document on the evaluation and treatment of moderate‐to‐severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology
Top Cited Papers
- 26 January 2016
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (S2), 1-18
- https://doi.org/10.1111/jdv.13542
Abstract
Psoriasis is a highly prevalent disease with a major impact on quality of life; therefore, appropriate patient management is mandatory. Given that many issues in psoriasis are controversial and not clearly defined by evidence‐based medicine, management of psoriasis is very variable. Expert consensus can generate practical guidelines for optimization of patient care. Much has changed since 2009, when the Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis was published by the Spanish Psoriasis Group (GEP) of the Spanish Academy of Dermatology and Venereology (AEDV). The objective of the present consensus document is to provide the dermatologist with updated recommendations for the evaluation and treatment of patients with moderate‐to‐severe plaque psoriasis. All active members of the GEP of the AEDV were invited to participate in the survey. The final group comprised 46 members from various areas of Spain and with substantial experience in managing psoriasis. A 3‐round Delphi process was used to reach consensus. Consistent agreement and consistent disagreement (consensus) required the achievement of at least two of the following three criteria: Criterion 1, which was based on the position occupied by the mean on a scale of 1–9 and an SD <2; Criterion 2, which was based on the median and interquartile range (IQR) on a scale of 1–9; Criterion 3, which considered the percentage of the voting experts on a scale of 1–9. The items studied were definition of severity, therapeutic objectives, indications for systemic treatment and biologic therapy, induction and maintenance periods, therapeutic failure, loss of response, relapse and rebound, continuous and intermittent therapy, screening of patients before treatment, adherence to therapy, follow‐up of treatment outcome, combination of drugs, transitioning and associated comorbidities. Consistent agreement or disagreement (consensus) was achieved for 198 items (agreement, 3 criteria 146 items, 2 criteria 43 items; disagreement, 3 criteria 9 items, 2 criteria 0 items) based on the criteria described above. Completion of the Delphi consensus process enabled a broad and experienced group of Spanish psoriasis experts to provide useful and practical guidelines for the management and treatment of patients with moderate‐to‐severe psoriasis, particularly in areas where evidence is lacking.Keywords
This publication has 59 references indexed in Scilit:
- Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: Results of a nationwide cohort study from TaiwanJournal of the American Academy of Dermatology, 2013
- Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm RegistryJournal of the European Academy of Dermatology and Venereology, 2013
- A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasisJournal of the European Academy of Dermatology and Venereology, 2013
- S3 – Guidelines on the treatment of psoriasis vulgaris (English version). UpdateJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2012
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusionsJournal of the American Academy of Dermatology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchiv für dermatologische Forschung, 2010
- The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus projectClinical Rheumatology, 2009
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)Archiv für dermatologische Forschung, 2007
- Current severe psoriasis and the Rule of TensBritish Journal of Dermatology, 2005